(EVO) Evotec SE Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVO) Evotec SE Complete Analysis Pack
See the Bigger Picture
This Evotec SE 4P's Marketing Mix Analysis shows how the company positions its products, sets prices, chooses distribution channels, and promotes offerings in one concise framework; the page includes a genuine preview/sample of the analysis so you can review style and content before buying — purchase the full version to get the complete, ready-to-use report.
Product
11 therapeutic areas
Evotec SE’s product is drug discovery and development services, built for biotechnology and pharmaceutical partners across 11 therapeutic areas. These span metabolic disorders, fibrosis, infectious diseases, CNS, oncology, pain, inflammation, immunology, rare diseases, respiratory conditions, and women’s health. This broad scope helps Evotec SE serve multiple pipelines at once, reducing partner dependence on any one disease area.
Discovery and advancement services
Evotec SE Discovery and advancement services help find and develop new drug candidates from early research through later-stage support. The model makes Evotec a research partner, not a drug seller, so value comes from science-led services and collaboration. This fits a market where pharma outsourcing keeps rising, with R&D spend in the industry above $250 billion a year.
B2B partnership model
Evotec SE’s B2B partnership model is built on collaboration contracts and shared programs with pharma and biotech clients, so the business is service-led and enterprise-focused. In its latest reported year, Evotec said partnerships with over 100 life sciences companies supported a revenue base near €800m, showing how deeply the model depends on long-term external programs.
Global R&D platform
Evotec SE runs a global R&D platform that lets it execute many programs at once across biology, chemistry, and discovery services. In 2024, the company reported revenue of €797.8 million, showing the scale that supports partner projects with more flexibility and faster handoffs across sites.
- Global setup supports multi-program delivery
- Covers several scientific disciplines
- Scales partner work across regions
Founded in 1993
Evotec was founded in 1993, and the move from Evotec AG to Evotec SE in April 2019 marked its shift into a European company structure. That 30-plus year operating history supports credibility in drug discovery and pharma innovation. In 2024, the Company employed about 5,000 people, showing its scale in life sciences.
- Founded in 1993; renamed in April 2019.
- 30-plus years in pharma innovation.
- About 5,000 employees in 2024.
Evotec: Broad Discovery Platform Powering 100+ Life Science Partners
Evotec SE’s product is its discovery and development service platform, not a drug portfolio. It spans 11 therapeutic areas and supports more than 100 life science partners, so the offer is broad and B2B-led.
| Key data | Value |
|---|---|
| Revenue | €797.8m |
| Employees | about 5,000 |
| Partners | 100+ |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Evotec SE’s Product, Price, Place, and Promotion strategies for clear strategic benchmarking.
Editable Excel File
Helps stakeholders quickly grasp Evotec SE’s 4Ps, turning a complex analysis into a clear, decision-ready summary.
Reference Sources
Provides a compact, traceable bibliography of industry reports and datasets to speed due diligence and validate Evotec SE assumptions.
Place
Hamburg, Germany
Evotec SE is headquartered in Hamburg, Germany, the company’s corporate base and main hub for global management and partner coordination. Hamburg is Germany’s second-largest city, with about 1.9 million residents, and its port-driven ecosystem supports international biotech and pharma links that fit Evotec SE’s partnership model.
Global operations
Evotec SE operates across Europe and North America, with more than 20 sites in key biotech hubs, including Germany, France, the UK, Austria, Italy, and the United States. This global footprint lets Company Name serve multinational biotech and pharma clients close to their R&D teams, while supporting faster project transfer across time zones and markets.
Direct B2B channels
Evotec SE sells through direct B2B channels, so partners buy research and development programs straight from the company. This model fits its fee-for-service and collaboration work, including drug discovery and platform-based projects. There is no retail or consumer distribution model, so customer access depends on corporate partnerships, not store sales.
Alliance network
Evotec SE’s alliance network is a core market route, linking it with Bayer AG, Eli Lilly, Novo Nordisk A/S, Pfizer Inc., Bristol Myers Squibb, and Takeda Pharmaceuticals. These ties keep Evotec plugged into multiple late-stage and discovery pipelines across big pharma. The model is partnership-led, so reach grows without relying on one customer.
- Six named pharma partners
- Broad pipeline access
- Low single-market dependence
Collaborative footprint
Evotec SE’s place strategy is built on collaboration sites and partner access, so science happens close to project needs, not at a shelf. In FY2024, Evotec SE reported €797.0 million in revenue, showing the scale behind this expertise-led network.
- Close-to-partner scientific execution
- Access to expertise drives reach
- FY2024 revenue: €797.0 million
Evotec’s Global Footprint Powers Faster Biotech Partnerships
Evotec SE’s place strategy is built on Hamburg HQ plus more than 20 sites in Europe and North America, so it stays close to biotech and pharma partners where R&D happens. That setup supports direct B2B delivery, faster project handoffs, and broad access to global pipelines.
| Place factor | Data |
|---|---|
| HQ | Hamburg, Germany |
| Sites | 20+ in Europe and North America |
| Model | Direct B2B partnerships |
Preview Before You Purchase
Evotec SE Reference Sources
The preview shown here is the exact, full Evotec SE 4P's Marketing Mix Analysis you'll receive instantly after purchase—no samples or placeholders, fully editable and ready to use.
Promotion
12 named partners
Evotec uses 12 named partners, including Bayer, Lilly, Pfizer, Takeda, and Bristol Myers Squibb, as a trust signal in its promotion. Public alliances with large pharma and biotech names help show external validation of its drug-discovery platform and support deal flow. The partner list is broad, spanning 12 firms across Europe, the US, and Asia.
Alliance announcements
Alliance announcements are a core promotion tool for Evotec SE, because they signal new projects, wider work, and scientific progress to investors and industry partners. In FY2024, Evotec reported revenue of about €797 million, so each new alliance helps support visibility around a large, active pipeline. These updates also reinforce trust by showing continued external demand for Company Name's science.
11 disease areas
Evotec promotes coverage across 11 disease areas, making breadth a core message in its market communication. That range shows the Company can work across multiple unmet medical needs, not just one niche. For investors, the key number is 11: it supports pipeline optionality, but it also raises execution complexity.
April 2019 rebrand
In April 2019, Company Name changed its name to Evotec SE, giving the business a modern European corporate identity while keeping its market name stable. The rebrand supports clear public-facing communication, so investors, partners, and scientists still recognize the same Company Name brand.
- April 2019: name changed to Evotec SE
- Supports a European corporate image
- Keeps communication continuity
Corporate reporting
Evotec SE uses corporate reporting to support promotion through investor updates and annual disclosures that stress partnerships, research depth, and strategic direction. The message is aimed at both capital markets and industry partners, so the materials link scientific progress with business execution.
- Investor updates reinforce partnership-led growth
- Reporting highlights research and platform strength
- Messaging targets capital markets and partners
Evotec’s Partner Network Fuels Brand Credibility and Growth
Promotion at Evotec SE is built on partner credibility: 12 named alliances, including Bayer, Lilly, Pfizer, Takeda, and Bristol Myers Squibb, act as proof points for the platform. Public deal news, investor reporting, and a 11-disease-area message keep the brand visible across science and capital markets. FY2024 revenue was about €797 million, so each update helps reinforce scale and pipeline activity.
| Promotion signal | Data |
|---|---|
| Named partners | 12 |
| Disease areas | 11 |
| FY2024 revenue | €797 million |
| Name change | April 2019 |
Price
Contract-specific pricing
Evotec SE does not publish a consumer price list; pricing is set case by case in B2B contracts. The final fee depends on project scope, timeline, and scientific complexity, so a target discovery program and a custom assay package can price very differently. This fits Evotec's 2025 revenue base of about €800 million, where contract work is tailored rather than off the shelf.
No public list price
Evotec SE prices its discovery and development services privately, so there is no public list price or posted rate. That fits specialized pharma contracts, where scope, milestones, and risk sharing are negotiated case by case. This model supports tailored deals across a business that reported 2025-scale revenues in the hundreds of millions of euros, rather than shelf pricing.
Project-based fees
Evotec SE uses project-based fees, so pricing is set per program rather than one fixed rate. Fees can change with the target, the program length, and the development stage, which fits early discovery through later work. That makes the model flexible for partners and helps align payment with program scope.
Shared-risk structure
Evotec SE’s shared-risk pricing fits its collaboration-led model: partners fund work in step with progress, so cash outlay rises only as a program advances. In 2023, Evotec SE reported revenue of €782.2 million, showing how its mix depends on pipeline milestones, research services, and partner-funded programs rather than fixed upfront fees.
- Cost is shared with partners.
- Payments track program milestones.
- Price follows value created.
- Lower upfront burden supports R&D.
Outcome-linked terms
Evotec SE often prices biotech partnerships with outcome-linked terms, so customers pay less upfront and more only when research or development targets are met. That structure fits the sector, where deals can include milestone payments in the tens of millions of euros and bigger success-based upside later.
This lowers early cash risk for partners while keeping Evotec SE exposed to long-term value if the program advances.
- Lower upfront cash outlay
- Payments tied to milestones
- Upside rises with success
Evotec’s Project-Based Pricing Drives ~€800m in 2025 Revenue
Price at Evotec SE is negotiated case by case, not posted on a public list. Fees depend on program scope, stage, and risk sharing, so partners pay less upfront and more as milestones are hit. That fits a 2025 revenue base of about €800 million from tailored B2B contracts.
| Metric | Value |
|---|---|
| 2025 revenue | ~€800m |
| Pricing model | Project-based |
| Payment timing | Milestone-linked |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.